Sponsor
VCSIP is supported by R01 HL105447 from the NHLBI with cofounding from the Office of Dietary Supplements (ODS). The ancillary study “Can Supplemental Vitamin C Lessen the Effects of Smoking in Pregnancy on the Placenta” is supported by a supplement to this award by the NHLBI with cofunding from the ODS. The ancillary study “Blocking Lung Disease and the Epigenetic Changes in Childhood Caused by Maternal Smoking During Pregnancy” is funded by a pilot award from the Oregon Clinical and Translational Research Institute (OCTRI) (UL1TR000128); we received additional support for data coordination through for the study was provided through OCTRI which is funded by the National Center for Advancing Translational Sciences (UL1TR000128).
Published In
Contemporary Clinical Trials
Document Type
Post-Print
Publication Date
7-2017
Subjects
Asthma, Vitamin C -- Therapeutic use, Pregnant women -- Tobacco use, Pulmonary function tests for newborn infants
Abstract
Despite strong anti-smoking efforts, at least 12% of American women cannot quit smoking when pregnant resulting in > 450,000 smoke-exposed infants born yearly. Smoking during pregnancy is the largest preventable cause of childhood respiratory illness including wheezing and asthma. Recent studies have shown a protective effect of vitamin C supplementation on the lung function of offspring exposed to in utero smoke in a non-human primate model and an initial human trial. Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) is a randomized, double-blind, placebo-controlled trial to evaluate pulmonary function at 3 months of age in infants delivered to pregnant smokers randomized to 500 mg/day of vitamin C versus placebo during pregnancy. Secondary aims evaluate the incidence of wheezing through 12 months and pulmonary function testing at 12 months of age. Women are randomized between 13 and 23 weeks gestation from clinical sites in Portland, Oregon at Oregon Health & Science University and PeaceHealth Southwest Medical Center and in Indianapolis, Indiana at Indiana University and Wishard Hospital. Vitamin C supplementation occurs from randomization to delivery. Monthly contact with participants and monitoring of medical records is performed to document medication adherence, changes in smoking and medical history, and adverse events. Pulmonary function testing of offspring occurs at 3 and 12 months of age and incidence of wheezing and respiratory illness through 12 months is captured via at least quarterly questionnaires. Ancillary studies are investigating the impact of vitamin C on placental blood flow and DNA methylation.
Locate the Document
DOI
10.1016/j.cct.2017.05.008
Persistent Identifier
http://archives.pdx.edu/ds/psu/20707
Citation Details
McEvoy, C. T., Milner, K. F., Scherman, A. J., Schilling, D. G., Tiller, C. J., Vuylsteke, B., ... & Peters, D. (2017). Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP): Rationale, design, and methods of a randomized, controlled trial of vitamin C supplementation in pregnancy for the primary prevention of effects of in utero tobacco smoke exposure on infant lung function and respiratory health. Contemporary Clinical Trials, 58, 66-77.
Description
This is the author's manuscript of the article published in final edited form at: https://doi.org/10.1016/j.cct.2017.05.008
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.